Cyclerion Therapeutics Inc (CYCN)
2.96
-0.09
(-2.95%)
USD |
NASDAQ |
Apr 23, 12:58
Cyclerion Therapeutics Research and Development Expense (Quarterly): 0.024M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.024M |
| September 30, 2023 | 0.58M |
| June 30, 2023 | 0.886M |
| March 31, 2023 | 3.773M |
| December 31, 2022 | 1.176M |
| September 30, 2022 | 1.414M |
| June 30, 2022 | 10.22M |
| March 31, 2022 | 9.743M |
| December 31, 2021 | 10.46M |
| September 30, 2021 | 7.032M |
| June 30, 2021 | 12.05M |
| March 31, 2021 | 8.092M |
| Date | Value |
|---|---|
| December 31, 2020 | 12.09M |
| September 30, 2020 | 13.70M |
| June 30, 2020 | 13.79M |
| March 31, 2020 | 16.82M |
| December 31, 2019 | 20.68M |
| September 30, 2019 | 22.30M |
| June 30, 2019 | 25.76M |
| March 31, 2019 | 26.40M |
| December 31, 2018 | 22.45M |
| September 30, 2018 | 21.50M |
| June 30, 2018 | 22.25M |
| March 31, 2018 | 21.51M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.024M
Minimum
Dec 2023
25.76M
Maximum
Jun 2019
10.03M
Average
10.22M
Median
Jun 2022
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.563B |
| iBio Inc | 1.535M |
| AbbVie Inc | 1.927B |
| Agile Therapeutics Inc | 0.054M |
| NovaBay Pharmaceuticals Inc | 0.004M |